Skip to main content
. Author manuscript; available in PMC: 2022 Aug 28.
Published in final edited form as: Cancer Lett. 2021 May 24;514:79–89. doi: 10.1016/j.canlet.2021.05.011

Figure 7. The p48-Cre; LSL-KRASG12D; p53lox/lox mice had too rapid PDAC progression to potentiate the effect of HMMRΔexon8-16.

Figure 7.

(A-C) H&E stain of representative PDAC from (A) a 9-week-old C0: p48-Cre; LSL-KRASG12D; p53lox/ lox mouse, (B) an 8-week-old C1: p48-Cre; LSL-KRASG12D; p53lox/ lox; HMMRΔexon8-16/WT mouse, and (C) a 9-week-old C2: p48-Cre; LSL-KRASG12D; p53lox/ lox; HMMRΔexon8-16/Δexon8-16 mouse. (D) Kaplan-Meier survival curve for C0: 67 mice, C1: 33 mice, and C2: 31 mice. Tukey adjusted P values from pairwise log-rank test were shown.